Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04965831 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2021 | clinicaltrials |
| NCT02824965 | Pembrolizumab + CVA21 in Advanced NSCLC | unknown | Phase 1 | 11 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04951648 | A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation | unknown | Phase 3 | 220 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04952168 | Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC | unknown | Phase 2 | 26 | Yuan ChenOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04950400 | A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC | unknown | N/A | 60 | Beijing Chest HospitalOTHER | 0 | Jul 6, 2021 | clinicaltrials |
| NCT04942301 | PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy | unknown | Phase 1 | 24 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04945200 | Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer | unknown | — | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04944069 | Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis(ATTRACT) | unknown | N/A | 69 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT04941417 | Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients | unknown | Phase 2 | 60 | Peking Union Medical CollegeOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT01711697 | An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 16 | Emory UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04541251 | Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC | unknown | Phase 2 | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04932343 | Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor | unknown | — | 20 | Samsung Medical CenterOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT03447678 | Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.(PEOPLE) | unknown | Phase 2 | 65 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04919616 | An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC) | unknown | Early Phase 1 | 15 | Shanghai OriginCell Therapeutics Co., Ltd.INDUSTRY | 0 | Jun 9, 2021 | clinicaltrials |
| NCT04905550 | Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC | unknown | Phase 2 | 50 | Chongqing University Cancer HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT04828395 | Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer(F&C) | unknown | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT04874844 | JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety | unknown | Phase 2 / Phase 3 | 420 | Beijing Dongfang Biotech Co., Ltd.INDUSTRY | 0 | May 10, 2021 | clinicaltrials |
| NCT04878692 | Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies(OPERA) | unknown | N/A | 96 | Hospices Civils de LyonOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04304248 | Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer(NeoTAP01) | unknown | Phase 2 | 30 | Hao LongOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | unknown | Phase 1 | 192 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04865705 | Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer | unknown | Phase 2 | 33 | West China HospitalOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04857970 | Routine Electronic Monitoring Of Quality Of Life -Poumon (REMOQOL-Poumon) | unknown | — | 72 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT04840290 | A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC | unknown | Phase 3 | 30 | Tang-Du HospitalOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT04825925 | Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments | unknown | N/A | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 12, 2021 | clinicaltrials |
| NCT04725448 | Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma | unknown | Phase 2 | 27 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826913 | High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization(TUMOVASC) | unknown | — | 100 | University Hospital, Strasbourg, FranceOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03878537 | Recurrence Monitoring in NSCLC Using Circulating Tumor DNA | unknown | — | 50 | Scripps Translational Science InstituteOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03373955 | A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients | unknown | — | 60 | Sichuan UniversityOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT02667743 | Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC | unknown | Phase 3 | 454 | Shanghai Yizhong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04722406 | Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy. | unknown | — | 350 | Sun Yat-sen UniversityOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04797806 | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC(SAINT) | unknown | Phase 3 | 206 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04793139 | Efficacy and Safety of Camrelizumab in Real-World Prospective Study | unknown | — | 1,000 | Guangdong Association of Clinical TrialsOTHER | 0 | Mar 11, 2021 | clinicaltrials |
| NCT04292119 | Lorlatinib Combinations in Lung Cancer | unknown | Phase 1 / Phase 2 | 96 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02927340 | A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions | unknown | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00643318 | CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer | unknown | Phase 2 | 40 | Accuray IncorporatedINDUSTRY | 2 | Mar 5, 2021 | clinicaltrials |
| NCT03976856 | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | unknown | Phase 1 | 42 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04137588 | Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | unknown | — | 126 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT04629027 | Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC | unknown | — | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT04768491 | Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC | unknown | — | 82 | Peking Union Medical CollegeOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT03986528 | Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 4 | 334 | Jie LiOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04761640 | The Impact of Polynuclear Neutrophils' Intra-tumoral Rate and the Mutational Status in Pulmonary Adenocarcinomas on Survival | unknown | — | 100 | Central Hospital, Nancy, FranceOTHER | 0 | Feb 21, 2021 | clinicaltrials |
| NCT04762030 | Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study | unknown | Phase 2 | 39 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04753918 | Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study | unknown | Early Phase 1 | 3 | Taoyuan General HospitalOTHER_GOV | 0 | Feb 15, 2021 | clinicaltrials |
| NCT04749407 | Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer | unknown | — | 50 | First People's Hospital of HangzhouOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04741633 | Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy(NSCLC) | unknown | — | 25 | Fudan UniversityOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT02500199 | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | unknown | Phase 1 | 50 | Hengrui Therapeutics, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Jul 16, 2021source: clinicaltrials